Chimeric Therapeutics Ltd Ordinary Shares CHM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.02
- Day Range
- A$0.02–0.02
- 52-Week Range
- A$0.02–0.05
- Bid/Ask
- A$0.02 / A$0.02
- Market Cap
- A$17.98 Mil
- Volume/Avg
- 1.3 Mil / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
Valuation
Metric
|
CHM
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.10 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
CHM
|
---|---|
Quick Ratio | 1.38 |
Current Ratio | 1.39 |
Interest Coverage | — |
Quick Ratio
CHM
Profitability
Metric
|
CHM
|
---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CHM
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tcdpbrxf | Dgkt | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qcryggp | Dmgpxrl | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vtwdpzyq | Jgbckn | $108.2 Bil | |
MRNA
| Moderna Inc | Qxcsvctc | Nzrt | $50.9 Bil | |
ARGX
| argenx SE ADR | Sqbgvmrx | Lmf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zptkyhwm | Lkvc | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Szfjzgbn | Zrwymh | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xxypcyqsy | Mbwbp | $14.6 Bil | |
INCY
| Incyte Corp | Lkynjscyp | Trsbq | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ctgbhtzsnk | Pxkhr | $12.3 Bil |